Literature DB >> 11481620

Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.

M G Donner1, D Keppler.   

Abstract

Cholestasis induces down-regulation of multidrug resistance protein 2 (Mrp2, symbol Abcc2), which is localized to the canalicular membrane. Given the overlapping substrate specificities of Mrp2 and multidrug resistance protein 3 (Mrp3, symbol Abcc3), we examined the hypothesis of a different subcellular and lobular localization of these members of the Mrp family in rat liver after bile duct ligation. We raised a polyclonal antibody against rat Mrp3 and detected this protein in the basolateral plasma membrane of hepatocytes surrounding the central veins and of cholangiocytes. The Mrp3 protein level was less than 2% of the expression observed after 72 hours of obstructive cholestasis. After 48 hours of bile duct ligation, the Mrp3 protein was increased and was further enhanced after 72 hours. In 72-hour-cholestatic rat liver Mrp3 was expressed, in addition, in periportal hepatocytes. However, there was a preponderance of Mrp3 in the pericentral area of the liver lobule. In Mrp2-deficient mutant rat liver, the Mrp3 protein expression was most enhanced and its zonation was lost. The Mrp3 immunostaining of cholangiocytes was preserved in cholestatic and in Mrp2-deficient mutant liver. Canalicular Mrp2 decreased and amounted to 34% of normal after bile duct ligation for 72 hours. We conclude that the hepatocellular up-regulation of Mrp3 in cholestasis together with cholangiocellular Mrp3 may compensate for the biliary obstruction and impaired canalicular Mrp2 function by clearing cholephilic anionic substances into the blood.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481620     DOI: 10.1053/jhep.2001.26213

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  59 in total

1.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

Review 2.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

3.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.

Authors:  Wensheng Chen; Shi-Ying Cai; Shuhua Xu; Lee A Denson; Carol J Soroka; James L Boyer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-01       Impact factor: 4.052

Review 5.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

6.  Effect of nine diets on xenobiotic transporters in livers of mice.

Authors:  Ying Guo; Julia Yue Cui; Hong Lu; Curtis D Klaassen
Journal:  Xenobiotica       Date:  2015-01-08       Impact factor: 1.908

Review 7.  Excretion of biliary compounds during intrauterine life.

Authors:  Rocio I R Macias; Jose J G Marin; Maria A Serrano
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 8.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

9.  Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.

Authors:  Noam Zelcer; Tohru Saeki; Ilse Bot; Annemieke Kuil; Piet Borst
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

10.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.